https://www.globenewswire.com/news-release/2024/01/03/2803143/0/en/XORTX-Submits-a-New-Patent-for-the-Treatment-of-Chronic-Kidney-Disease.html
CALGARY, Alberta, Jan. 03, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces submission of a new patent for the treatment of chronic kidney disease (“CKD”). This patent is designed to protect new discoveries and strategies for the treatment of individuals with varied degrees of kidney function in the setting of CKD. Importantly, this patent entitled “Oral and Sublingual Formulations of Xanthine Oxidase Inhibitors and Methods of Treating Disease” outlines new formulations and methods for safer and more effective the use of xanthine oxidase inhibitors (XOI) in the setting of CKD in particular autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy (DN), IgA nephropathy, lupus nephritis and focal segmental glomerulosclerosis.
The positive topline results from the XRX-OXY-101 bridging pharmacokinetic clinical study reported in Q1 2023 (the “Study”) characterized the pharmacokinetics of the Company’s proprietary formulation of oral oxypurinol, XORLO™. Results from the Study showed that XORLO™ was well tolerated by the 88 subjects who received the drug. There were no safety concerns during the testing of drug across the various dosing regimens used. Overall results were positive and showed: i) a substantial increase in the bioavailability of oxypurinol with the XORLO™ formulation platform; (ii) a substantially increased dose proportionality compared to non-formulated oxypurinol; (iii) a multiple dosing regimen that achieved therapeutic target values. In simple terms, substantially increased early oral absorption of XORLO™, and increased circulating concentrations of oxypurinol necessary to inhibit production of uric acid across the desired therapeutic range and thereby slow down the advancements of CKD. Each of these results will provide key data to facilitate precise dosing recommendations for upcoming registration trials in individuals with progressing kidney disease due to ADPKD as well as other causes of CKD.
Dr. Allen Davidoff, CEO of XORTX, commented, “The Bridging Pharmacokinetic Study reported this year provided a wealth of clinical data regarding the potential substantive benefit of the novel formulations of the xanthine inhibitor class of drugs. Analysis of this data set, the use of in silico based pharmacokinetic modeling of data from the XRX-OXY-101 clinical trial, and further innovation, resulted in a deeper understanding of how to address the challenges of dosing in progressing kidney disease. This patent application is intended to claim new opportunities to enhance how the xanthine oxidase inhibitor class of drugs may be dosed in the future. Importantly, how to further improve the safe and effective administration of this class of drugs, including oxypurinol.”
Recent XRTX News
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:10:54 PM
- XORTX Reprices Warrants Issued in Connection with Previous Private Placements • GlobeNewswire Inc. • 04/30/2024 05:54:49 PM
- XORTX Announces Publication of Key Research in ADPKD • GlobeNewswire Inc. • 04/22/2024 11:00:00 AM
- XORTX Welcomes New Member to the Board of Directors • GlobeNewswire Inc. • 04/08/2024 11:30:00 AM
- XORTX Announces Participation in Spring 2024 Investor Conferences • GlobeNewswire Inc. • 04/08/2024 11:00:00 AM
- XORTX Announces New Clinical Advisory Board Member • GlobeNewswire Inc. • 03/27/2024 09:00:00 AM
- XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial • GlobeNewswire Inc. • 03/19/2024 09:00:00 AM
- XORTX Reprices Warrants Issued in Connection with Previous Private Placements • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units • GlobeNewswire Inc. • 03/04/2024 12:00:00 PM
- XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units • GlobeNewswire Inc. • 02/15/2024 12:00:00 PM
- XORTX Files an Amended and Restated Prospectus Supplement for the Offering of Units • GlobeNewswire Inc. • 02/02/2024 01:46:09 AM
- XORTX Announces $2 Million Public Offering • GlobeNewswire Inc. • 01/15/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/03/2024 12:25:58 PM
- XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/02/2024 01:12:44 PM
- XORTX Welcomes New Member to the Board of Directors • GlobeNewswire Inc. • 01/02/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/30/2023 09:04:02 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/30/2023 12:30:05 PM
- XORTX Announces US ATM Offering • GlobeNewswire Inc. • 11/30/2023 12:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/30/2023 02:57:42 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/29/2023 12:00:05 PM
- XORTX Meets Nasdaq Continued Listing Requirements • GlobeNewswire Inc. • 11/29/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/13/2023 12:00:11 PM
- XORTX Clarifies Timing for Share Consolidation • GlobeNewswire Inc. • 11/10/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/08/2023 10:00:08 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM